Novartis gets FDA approval for expanded use of Tasigna

06/17/2010 | Wall Street Journal, The

The FDA authorized Novartis to promote Tasigna as a treatment for adults in earlier stages of Philadelphia chromosome-positive chronic myeloid leukemia. The drug was approved in October 2007 for patients whose disease had progressed or who failed to respond to other treatments, including Novartis' Gleevec.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL